Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Conditions:   FGFR1 Gene Amplification;   FGFR1 Gene Mutation;   FGFR1 Gene Translocation;   FGFR2 Gene Amplification;   FGFR2 Gene Mutation;   FGFR2 Gene Translocation;   FGFR3 Gene Amplification;   FGFR3 Gene Mutation;   FGFR3 Gene Translocation;   Metastatic Colorectal Carcinom a;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal  Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Colorectal Carcinoma Interventions:   Drug: Pemigatinib;   Other: Quality-of-Life Assessment Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials